Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.90B | 1.24B | 933.01M | 701.89M | 540.10M |
Gross Profit | 1.58B | 1.09B | 793.02M | 604.84M | 476.72M |
EBITDA | 333.06M | -439.20M | -582.12M | -306.08M | -453.38M |
Net Income | 235.24M | -535.98M | -703.49M | -418.78M | -554.13M |
Balance Sheet | |||||
Total Assets | 3.96B | 3.26B | 3.13B | 3.15B | 2.98B |
Cash, Cash Equivalents and Short-Term Investments | 1.35B | 1.68B | 1.99B | 2.12B | 1.94B |
Total Debt | 1.34B | 1.40B | 1.62B | 1.14B | 1.07B |
Total Liabilities | 2.44B | 2.41B | 2.74B | 2.22B | 2.22B |
Stockholders Equity | 1.53B | 859.34M | 384.95M | 928.01M | 761.76M |
Cash Flow | |||||
Free Cash Flow | -342.74M | -588.34M | -356.17M | -481.66M | 25.26M |
Operating Cash Flow | -205.79M | -500.99M | -325.35M | -443.17M | 107.47M |
Investing Cash Flow | 755.56M | -165.80M | -1.05B | 495.41M | -121.72M |
Financing Cash Flow | 124.81M | 125.00M | 232.51M | 561.57M | 682.32M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $4.37B | 12.63 | 25.71% | ― | -12.31% | -17.53% | |
61 Neutral | $8.14B | ― | -20.01% | ― | 112.54% | 54.30% | |
54 Neutral | $5.24B | ― | -282.16% | ― | 72.16% | 9.65% | |
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% | |
52 Neutral | $6.99B | ― | -36.68% | ― | -100.00% | 5.49% | |
50 Neutral | $8.37B | ― | -47.71% | ― | 99.19% | 48.43% | |
47 Neutral | $1.27B | 19.61 | -23.61% | ― | 59.15% | -1881.09% |
On July 21, 2025, Sarepta Therapeutics announced that the FDA placed a clinical hold on its investigational gene therapy trials for LGMD, affecting several of its product candidates. This follows a strategic restructuring process announced on July 16, 2025, where the company paused LGMD programs except SRP-9003, for which it completed Phase 3 enrollment and dosing in December 2024. Sarepta plans to discuss with the FDA a potential pathway for accelerated approval of SRP-9003 after the hold is lifted. Additionally, the FDA revoked the platform technology designation for Sarepta’s AAVrh74 platform, initially granted in June 2025.
The most recent analyst rating on (SRPT) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.
On July 14, 2025, Sarepta Therapeutics announced a strategic restructuring plan, including a 36% workforce reduction, to prioritize high-value programs and ensure long-term financial sustainability. The company aims to save approximately $400 million annually and focus on its siRNA platform, while also updating the ELEVIDYS label with a black box warning for acute liver issues. Key executive appointments were made, and the company reported preliminary second-quarter 2025 financial results, with total net product revenue of $513 million.
The most recent analyst rating on (SRPT) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.
On June 5, 2025, Sarepta Therapeutics held its annual meeting where stockholders approved amendments to the company’s equity and employee stock purchase plans, increasing the number of shares available under these plans. Additionally, stockholders elected new directors, approved executive compensation, and ratified KPMG as the independent auditor, indicating strong shareholder support for the company’s strategic initiatives and governance.
The most recent analyst rating on (SRPT) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.